← Back to headlines
TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio
TriSalus Life Sciences has reaffirmed its revenue guidance of $60M–$62M for 2026 and announced the expansion of its PEDD portfolio.
5 Mar, 23:26 — 5 Mar, 23:26
ℹOnly 1 source covers this story
